FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Monte S. Buchsbaum; M. Mehmet Haznedar; Jonathan Aronowitz; Adam M. Brickman; Randall E. Newmark; Rachel Bloom; Jesse Brand; Kim E. Goldstein; Desmond Heath; Meghan Starson; Erin A. Hazlett

doi:10.1016/j.schres.2007.04.027

FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Monte S. Buchsbaum, M. Mehmet Haznedar, Jonathan Aronowitz, Adam M. Brickman, Randall E. Newmark, Rachel Bloom, Jesse Brand, Kim E. Goldstein, Desmond Heath, Meghan Starson, Erin A. Hazlett

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR = 24, TE = 5, flip angle 40°, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.

Original language	English
Pages (from-to)	293-305
Number of pages	13
Journal	Schizophrenia Research
Volume	94
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2007.04.027
State	Published - Aug 2007
Externally published	Yes

Bibliographical note

Funding Information:
The project data collection was partly supported by Eli Lilly and Company.

Funding Information:
Dr. Richard Pico contributed to the initial planning of the project. Dr. Eileen DiFrancesco assisted in the recruitment of patients. This research was supported by a grant from the National Intsitute of Mental Health, Anatomy and function of the thalamus in schizophrenia MH60023, and by General Clinical Research Center CRC grant # 5-M01 RR00071. The data collection was supported by an investigator-initiated grant from Eli Lilly and Company.

Funding Information:
This work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health (MH60023, MH56489, MH60384S). The study was designed by the first author, and elements of the data analysis and presentation supported by these other sources. The authors have no financial interest in the project outcome.

Funding Information:
This pharmacoimaging work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health for the study of schizophrenia (MH60023, MH56489, MH60384S). The study was designed by the first author and elements of the data collection, analysis and presentation supported by these sources. The authors worked together on the analysis of data. The funding sources all favored the authors in their efforts to report the scientific findings and we appreciate their flexibility and patience.

Keywords

Early onset
Hypofrontality
Neuroleptic
Schizophrenia
Striatum
Thalamus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2007.04.027

Cite this

@article{edc0d7d0ccb143a0a1571646c5b30e66,

title = "FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol",

abstract = "We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR = 24, TE = 5, flip angle 40°, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.",

keywords = "Early onset, Hypofrontality, Neuroleptic, Schizophrenia, Striatum, Thalamus",

author = "Buchsbaum, {Monte S.} and Haznedar, {M. Mehmet} and Jonathan Aronowitz and Brickman, {Adam M.} and Newmark, {Randall E.} and Rachel Bloom and Jesse Brand and Goldstein, {Kim E.} and Desmond Heath and Meghan Starson and Hazlett, {Erin A.}",

note = "Funding Information: The project data collection was partly supported by Eli Lilly and Company. Funding Information: Dr. Richard Pico contributed to the initial planning of the project. Dr. Eileen DiFrancesco assisted in the recruitment of patients. This research was supported by a grant from the National Intsitute of Mental Health, Anatomy and function of the thalamus in schizophrenia MH60023, and by General Clinical Research Center CRC grant # 5-M01 RR00071. The data collection was supported by an investigator-initiated grant from Eli Lilly and Company. Funding Information: This work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health (MH60023, MH56489, MH60384S). The study was designed by the first author, and elements of the data analysis and presentation supported by these other sources. The authors have no financial interest in the project outcome. Funding Information: This pharmacoimaging work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health for the study of schizophrenia (MH60023, MH56489, MH60384S). The study was designed by the first author and elements of the data collection, analysis and presentation supported by these sources. The authors worked together on the analysis of data. The funding sources all favored the authors in their efforts to report the scientific findings and we appreciate their flexibility and patience. ",

year = "2007",

month = aug,

doi = "10.1016/j.schres.2007.04.027",

language = "אנגלית",

volume = "94",

pages = "293--305",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier B.V.",

number = "1-3",

}

TY - JOUR

T1 - FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

AU - Buchsbaum, Monte S.

AU - Haznedar, M. Mehmet

AU - Aronowitz, Jonathan

AU - Brickman, Adam M.

AU - Newmark, Randall E.

AU - Bloom, Rachel

AU - Brand, Jesse

AU - Goldstein, Kim E.

AU - Heath, Desmond

AU - Starson, Meghan

AU - Hazlett, Erin A.

N1 - Funding Information: The project data collection was partly supported by Eli Lilly and Company. Funding Information: Dr. Richard Pico contributed to the initial planning of the project. Dr. Eileen DiFrancesco assisted in the recruitment of patients. This research was supported by a grant from the National Intsitute of Mental Health, Anatomy and function of the thalamus in schizophrenia MH60023, and by General Clinical Research Center CRC grant # 5-M01 RR00071. The data collection was supported by an investigator-initiated grant from Eli Lilly and Company. Funding Information: This work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health (MH60023, MH56489, MH60384S). The study was designed by the first author, and elements of the data analysis and presentation supported by these other sources. The authors have no financial interest in the project outcome. Funding Information: This pharmacoimaging work was supported by an investigator-initiated grant from Eli Lilly, and by grants from the National Center for Research Resources (M01-RR-00071), and the National Institute of Mental Health for the study of schizophrenia (MH60023, MH56489, MH60384S). The study was designed by the first author and elements of the data collection, analysis and presentation supported by these sources. The authors worked together on the analysis of data. The funding sources all favored the authors in their efforts to report the scientific findings and we appreciate their flexibility and patience.

PY - 2007/8

Y1 - 2007/8

N2 - We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR = 24, TE = 5, flip angle 40°, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.

AB - We acquired Positron emission tomography with 18-F-deoxyglucose (FDG-PET) and anatomical MRI in 30 never-previously medicated psychotic adolescents (ages 13-20). (FDG-PET) was obtained at baseline and after 8-9 weeks of a randomized double-blind trial of either olanzapine or haloperidol. Neuropsychological tests of executive function were also obtained. Patients carried out the serial verbal learning task, a modification of the California Verbal Learning Test, during the uptake of the FDG. PET scans were coregistered with spoiled gradient MRI (TR = 24, TE = 5, flip angle 40°, slice thickness 1.2 mm, field of view 230 mm) for accurate anatomical identification of regions of interest traced on the MRI. Twenty-two of the thirty patients completed the second PET and clinical evaluation. Individuals treated with olanzapine increased relative metabolic rates in the frontal lobe more than the occipital lobe while patients treated with haloperidol failed to increase frontal metabolic rates and did not show an anteroposterior gradient in medication response. Haloperidol increased striatal metabolic rate more than olanzapine. Both drugs increased thalamic metabolic rates and this increase was significantly larger in younger (age 13-15) than older (16-21) patients.

KW - Early onset

KW - Hypofrontality

KW - Neuroleptic

KW - Schizophrenia

KW - Striatum

KW - Thalamus

UR - http://www.scopus.com/inward/record.url?scp=34447098874&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2007.04.027

DO - 10.1016/j.schres.2007.04.027

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17574821

AN - SCOPUS:34447098874

SN - 0920-9964

VL - 94

SP - 293

EP - 305

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -

FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this